Divine Aleru, Microbiome Signatures Research Coordinator

This systematic review and meta-analysis evaluate the effectiveness of boric acid as a local drug delivery agent in treating periodontitis, highlighting its positive impact on periodontal health, particularly in probing pocket depth and clinical attachment level.

This review discusses the effectiveness of boric acid vaginal suppositories in treating azole-resistant vaginitis, including its benefits and limitations.

What was studied? This study investigated the in vitro efficacy of boric acid as an antiseptic agent against Pseudomonas aeruginosa strains isolated from diabetic foot infections. The research aimed to determine whether boric acid could serve as a viable alternative for local wound treatment, particularly given the rising issue of antibiotic resistance in diabetic foot […]

Clindamycin is an antibiotic commonly used to treat a variety of bacterial infections, including skin, bone, joint infections, and bacterial vaginosis. Known for its ability to target Gram-positive bacteria and anaerobes, Clindamycin disrupts protein synthesis in bacteria, halting their growth. While highly effective, its impact on the gut microbiome and the potential for Clostridium difficile infections make it essential to use with caution in certain populations.

This review analyzes clindamycin’s evidence-based use in infections, its anti-toxin benefits, and microbiome risks, especially C. difficile impact.

This review details clindamycin’s anti-inflammatory role in acne, showing its impact on C. acnes, cytokines, and immune responses beyond bacterial suppression.

What Was Reviewed? This review paper focuses on the scientific rationale and clinical basis for using clindamycin in treating dermatologic diseases. It details clindamycin’s antibacterial and anti-inflammatory roles, particularly its established use in acne vulgaris, folliculitis, rosacea, hidradenitis suppurativa (HS), and staphylococcal infections. The authors also explore its mechanism of action, highlighting how clindamycin inhibits […]

Tinidazole is a nitroimidazole antimicrobial that selectively targets anaerobic bacteria and protozoa, reshaping the gut ecosystem by depleting pathogenic anaerobes while preserving commensals. Clinically validated for giardiasis, bacterial vaginosis, and colorectal surgery prophylaxis. Its DNA-disrupting and biofilm-penetrating actions reduce inflammatory triggers and create niches for healthy microbiota to rebound.

This study shows that oral probiotics significantly boost cure rates of bacterial vaginosis when used with tinidazole, restoring a healthy vaginal microbiome.

This review evaluates tinidazole’s antibacterial efficacy, pharmacokinetics, and clinical utility in anaerobic infections, highlighting its broad-spectrum activity and potential microbiome implications.

A high glycemic load diet increases bacterial vaginosis (BV) risk, while nutrient-rich diets lower it. This study highlights the link between diet quality and vaginal microbiome balance, providing insights for clinicians on how dietary interventions may help prevent BV.

This review explores insulin resistance as a primary driver of PCOS, detailing molecular signaling defects and their clinical consequences. It provides critical insight into how hyperinsulinemia fuels both metabolic dysfunction and androgen excess, reinforcing PCOS as a systemic endocrine-metabolic disorder, with implications for microbiome-linked disease signatures.

This study shows reduced gut microbiota diversity and increased GABA-producing bacteria in PCOS, linking microbial shifts to elevated LH levels and supporting a gut–brain axis mechanism. The findings highlight microbial contributions to neuroendocrine dysfunction and suggest therapeutic avenues through microbiome-targeted interventions.

This Mendelian randomization study identifies a bidirectional causal link between specific gut microbes and PCOS. Bacilli and Burkholderiales increase PCOS risk, while Blautia and Cyanobacteria show protective effects. Findings reveal gut microbial signatures that may be targeted for PCOS treatment.

This review links dysbiosis of gut and vaginal microbiota to PCOS pathogenesis, highlighting reduced Lactobacillus, elevated Bacteroides, and hormonal imbalance. It supports microbiome-targeted therapies like FMT and probiotics as promising interventions, emphasizing the role of microbiota in regulating hormones, immunity, and metabolic function.

This review introduces the DOGMA theory linking gut dysbiosis and leaky gut to insulin resistance, inflammation, and hyperandrogenism in PCOS. It outlines a compelling rationale for microbiome-targeted therapies using prebiotics and probiotics.

This review connects gut microbiota dysbiosis to insulin resistance and hyperandrogenism in PCOS, identifying reduced SCFA producers and increased LPS-producing microbes as key signatures. It supports microbiota-targeted therapies as promising treatments for metabolic and reproductive symptoms in PCOS.

This review presents PCOS as a multisystem disorder driven by gut dysbiosis, neuroendocrine disruption, and adipose androgen synthesis. Targeting B. vulgatus, IL-22, and AKR1C3 may offer novel interventions.

This review links PCOS to gut microbiota dysbiosis, showing how LPS leakage, SCFA deficiency, and altered bile acids contribute to insulin resistance and hyperandrogenism. Microbiome-based therapies, including probiotics, prebiotics, and IL-22, show strong promise.

This study reveals that women with PCOS have altered gut fungal communities, marked by enriched Saccharomyces and depleted Aspergillus. These shifts may contribute to inflammation, metabolic stress, and endocrine disruption, highlighting fungi as critical players in PCOS pathophysiology.

This study reveals disrupted diurnal rhythms and significant dysbiosis in the salivary microbiota of PCOS patients, notably elevated Fusobacterium and reduced Actinobacteria. These oral microbial patterns may influence systemic metabolic and hormonal dysregulation.

This study demonstrates that gut dysbiosis in PCOS is not just correlative but causative. FMT and Lactobacillus transplantation restored hormonal balance and ovarian morphology in PCOS rats, confirming gut microbiota as a viable therapeutic target.

This study shows that gut microbiota dysbiosis in PCOS correlates with altered serum metabolites, including elevated LPCs and reduced citric acid. Roseburia and Prevotella_9 were linked to protective metabolic profiles, while Escherichia-Shigella was associated with inflammation and lipid imbalance.

This study explores the gut microbiota in women with PCOS and dyslipidemia, revealing significant microbial imbalances associated with lipid metabolism and hormonal dysregulation, offering potential targets for future therapies.